Tag: GPS Cancer

Filter

Thought Leadership

Product

Community

NantHealth
NantHealth and NantOmics Announce GPS Cancer® Platform May Improve Clinical Trial Design of Combination Strategies by Identifying Previously Unrecognized Cancer...
Findings Presented at the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium Orlando, FL and Culver City, CA – February 19, 2020 –...
NantHealth
Precision Insights
Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients
NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium SAN FRANCISCO–(BUSINESS WIRE)–Jan. 25, 2020– NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based,...
Precision Insights
Precision Insights
NantHealth Expands GPS Cancer™ Coverage Through Partnership With Horizon Blue Cross Blue Shield of New Jersey and COTA
New Jersey’s largest health insurance plan to reimburse for comprehensive molecular test in investigational cancer studies across four mid-Atlantic health...
Precision Insights
Precision Insights
NantHealth Partners with Children’s Hospital of Orange County to Revolutionize Pediatric Cancer Care Through the Use of GPS CancerTM
GPS Cancer will allow physicians to identify personalized treatments for children with rare, refractory or recurrent cancers for whom conventional...
Precision Insights
Precision Insights
Phoenix Children’s Hospital Selects NantHealth’s Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care
One of the nation’s leading pediatric hospitals to adopt GPS Cancer™, a comprehensive molecular testing platform for personalized cancer therapy,...
Precision Insights